Tango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights
Tango Therapeutics (NASDAQ: TNGX) reported Q3 2024 financial results and business updates. The company highlighted positive clinical activity for TNG462 across multiple tumor types, including a 43% ORR in cholangiocarcinoma. A new clinical collaboration with Revolution Medicines was established to evaluate TNG462 combinations. The company reported $293.3 million in cash, with runway into Q3 2026. Q3 2024 financial results showed collaboration revenue of $11.6 million and a net loss of $29.2 million ($0.27 per share). R&D expenses increased to $33.3 million, up from $27.1 million in Q3 2023.
Tango Therapeutics (NASDAQ: TNGX) ha riportato i risultati finanziari e gli aggiornamenti aziendali del terzo trimestre 2024. L'azienda ha sottolineato l'attività clinica positiva per TNG462 su più tipi di tumori, compreso un tasso di risposta obiettiva (ORR) del 43% nel colangiocarcinoma. È stata stabilita una nuova collaborazione clinica con Revolution Medicines per valutare le combinazioni di TNG462. L'azienda ha segnalato 293,3 milioni di dollari in contante, con una proiezione di liquidità fino al terzo trimestre 2026. I risultati finanziari del terzo trimestre 2024 hanno mostrato un fatturato da collaborazioni di 11,6 milioni di dollari e una perdita netta di 29,2 milioni di dollari (0,27 dollari per azione). Le spese di ricerca e sviluppo sono aumentate a 33,3 milioni di dollari, rispetto ai 27,1 milioni di dollari nel terzo trimestre 2023.
Tango Therapeutics (NASDAQ: TNGX) informó sobre los resultados financieros y las actualizaciones comerciales del tercer trimestre de 2024. La compañía destacó la actividad clínica positiva de TNG462 en múltiples tipos de tumores, incluidos un 43% de tasa de respuesta objetiva (ORR) en colangiocarcinoma. Se estableció una nueva colaboración clínica con Revolution Medicines para evaluar las combinaciones de TNG462. La compañía reportó 293,3 millones de dólares en efectivo, con recursos suficientes hasta el tercer trimestre de 2026. Los resultados financieros del tercer trimestre de 2024 mostraron ingresos por colaboraciones de 11,6 millones de dólares y una pérdida neta de 29,2 millones de dólares (0,27 dólares por acción). Los gastos de I+D aumentaron a 33,3 millones de dólares, frente a los 27,1 millones de dólares del tercer trimestre de 2023.
탱고 테라퓨틱스 (NASDAQ: TNGX)가 2024년 3분기 재무 결과 및 사업 업데이트를 보고했습니다. 회사는 TNG462가 다수의 종양 유형에서 긍정적인 임상 활동을 보였으며, 담관암에서 43%의 객관적 반응률(ORR)을 기록했다고 강조했습니다. TNG462 조합을 평가하기 위해 Revolution Medicines와의 새로운 임상 협력이 체결되었습니다. 회사는 2억 9천 3백만 달러의 현금을 보유하고 있으며, 2026년 3분기까지의 자금이 확보되어 있습니다. 2024년 3분기 재무 결과는 협력 수익이 1천 1백 60만 달러 및 순손실이 2천 9백 20만 달러(주당 0.27달러)라고 밝혔습니다. 연구 개발 비용은 3천 3백만 달러로 증가했으며, 이는 2023년 3분기의 2천 7백 10만 달러에서 증가한 수치입니다.
Tango Therapeutics (NASDAQ: TNGX) a annoncé ses résultats financiers et ses mises à jour commerciales pour le troisième trimestre 2024. La société a mis en avant une activité clinique positive pour TNG462 à travers plusieurs types de tumeurs, avec un taux de réponse objective (ORR) de 43% dans le cholangiocarcinome. Une nouvelle collaboration clinique avec Revolution Medicines a été établie pour évaluer les combinaisons de TNG462. La société a rapporté 293,3 millions de dollars en liquidités, avec une marge de manœuvre jusqu'au troisième trimestre 2026. Les résultats financiers du troisième trimestre 2024 ont montré des revenus de collaboration de 11,6 millions de dollars et une perte nette de 29,2 millions de dollars (0,27 dollar par action). Les dépenses de recherche et développement ont augmenté à 33,3 millions de dollars, contre 27,1 millions de dollars au troisième trimestre 2023.
Tango Therapeutics (NASDAQ: TNGX) hat die finanziellen Ergebnisse und Geschäftsupdates für das dritte Quartal 2024 bekannt gegeben. Das Unternehmen hob die positive klinische Aktivität von TNG462 über mehrere Tumorarten hervor, einschließlich einer objektiven Ansprechrate (ORR) von 43% beim Cholangiokarzinom. Eine neue klinische Zusammenarbeit mit Revolution Medicines wurde etabliert, um Kombinationen von TNG462 zu bewerten. Das Unternehmen meldete 293,3 Millionen Dollar in bar, mit finanzieller Deckung bis ins dritte Quartal 2026. Die finanziellen Ergebnisse des dritten Quartals 2024 zeigten Kooperationsumsätze von 11,6 Millionen Dollar und einen Nettoverlust von 29,2 Millionen Dollar (0,27 Dollar pro Aktie). Die F&E-Ausgaben erhöhten sich auf 33,3 Millionen Dollar, verglichen mit 27,1 Millionen Dollar im dritten Quartal 2023.
- Strong cash position of $293.3M with runway into Q3 2026
- Positive clinical activity for TNG462 with 43% ORR in cholangiocarcinoma
- Strategic collaboration with Revolution Medicines for combination trials
- Collaboration revenue increased to $11.6M in Q3 2024 from $10.7M in Q3 2023
- Net loss increased to $29.2M in Q3 2024 from $22.3M in Q3 2023
- R&D expenses increased 23% to $33.3M compared to Q3 2023
- TNG908 showed no activity in glioblastoma patients
- G&A expenses increased to $11.2M from $9.2M in Q3 2023
Insights
The Q3 results reveal a strong financial position with
The clinical data presents significant progress in PRMT5 inhibition strategy. TNG462 shows promising efficacy with
– Positive TNG462 clinical activity across multiple tumor types in the phase 1/2 clinical trial, program moving into full development with multiple combination studies –
– Clinical collaboration established with Revolution Medicines to evaluate TNG462 in combination with RAS(ON) multi- and G12D-selective inhibitors –
– Next-generation brain-penetrant MTA-cooperative PRMT5 inhibitor, TNG456, planned to enter the clinic in 1H 2025 –
– Strong cash position of
“We have made great progress with our PRMT5 development program, including positive data from the TNG462 phase 1/2 clinical trial that showcase the best-in-class potential of TNG462 in multiple tumor types, including pancreatic and non-small cell lung cancers (NSCLC). Based on these early data, we are advancing TNG462 into trials with multiple targeted and standard of care combinations, including two RAS(ON) tri-complex inhibitors from Revolution Medicines. Given that nearly all MTAP-deleted pancreatic cancer has a co-occurring RAS mutation, we believe this could be a powerful approach to changing the treatment landscape for this challenging cancer,” said Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics. “As part of the expanded capabilities needed to rapidly move TNG462 development forward, Dr. Maeve Waldron-Lynch, M.D. is joining Tango as Senior Vice President, Head of Clinical Development. Dr. Waldron-Lynch has extensive late-stage oncology clinical development and regulatory experience and will be invaluable as we prepare to advance TNG462 to registration.”
In a separate press release issued earlier today, Tango Therapeutics provided an update on its ongoing PRMT5 clinical development program:
-
Data from the ongoing phase 1/2 clinical trial of TNG462, a potentially best-in-class MTA-cooperative PRMT5 inhibitor, demonstrate clinical activity across multiple tumor types, including NSCLC and pancreatic cancer. Of note, this includes an ORR of
43% in cholangiocarcinoma (n=7). Substantive durability and a good safety and tolerability profile also were observed in this ongoing trial. The next clinical update is expected in 2025. - The Company plans to initiate multiple targeted and standard of care combinations with TNG462 including RAS(ON) multi-selective and RAS(ON) G12D-selective inhibitors (Revolution Medicines), osimertinib (AstraZeneca) and pembrolizumab (Merck). These studies are expected to begin enrolling in 1H 2025.
-
TNG908, an MTA-cooperative brain-penetrant PRMT5 inhibitor, is clinically active and well-tolerated across non-CNS cancers in the phase 1/2 clinical trial. In particular, there were a total of nine evaluable pancreatic cancer patients, two with partial responses (ORR
22% ) and five with stable disease as best response to date. The five ongoing pancreatic cancer patients have been on study for an average of 24 weeks, the longest for 72 weeks. - TNG908 did not demonstrate activity in glioblastoma (n=23 at active doses) likely because CNS exposure did not meet the required exposure threshold for clinical efficacy.
- TNG908 enrollment is being stopped to allow full resourcing of TNG462 as a potential best-in-class molecule. In particular, the notably longer time on treatment observed – 24 weeks and still increasing for TNG462 versus 16 weeks for TNG908 – the superior target coverage, and the safety and tolerability profile all support selection of TNG462 for further development.
- TNG456 is a next-generation brain-penetrant MTA-cooperative PRMT5 inhibitor that is 55X selective for MTAP deletion with 20 nM potency. Preclinical studies suggest TNG456 central nervous system exposure has the potential to be sufficient for meaningful efficacy in glioblastoma and brain metastases.
- The Company expects to begin enrolling patients in the planned phase 1/2 trial during 1H 2025.
Business Highlights
Clinical collaboration with Revolution Medicines
- In November 2024, the Company entered into a clinical collaboration with Revolution Medicines to evaluate the efficacy and safety of TNG462 in combination with RMC-6236, a RAS(ON) multi-selective inhibitor, and with RMC-9805, a RAS(ON) G12D-selective inhibitor.
- The agreement provides that Revolution Medicines will supply RMC-6236 and RMC-9805 to Tango and that Tango will be the sponsor of any combination trials. Each company will retain commercial rights to their respective compounds and the agreement is mutually non-exclusive.
TNG260, a first-in-class, highly selective CoREST complex inhibitor
- The TNG260 phase 1/2 clinical trial is ongoing, evaluating safety, pharmacokinetics, pharmacodynamics and efficacy of TNG260 in combination with pembrolizumab in patients with locally advanced or metastatic solid tumors with an STK11 loss-of-function mutation. To date, safety, tolerability and pharmacokinetic profiles are favorable.
-
STK11 mutations occur in approximately
15% of non-small cell lung,15% of cervical,10% of carcinoma of unknown primary,5% of breast and3% of pancreatic cancers.
Upcoming Milestones
- TNG462 clinical data update expected in 2025
- TNG462 combination trial enrollment expected to begin 1H 2025
- TNG456 phase 1/2 trial enrollment expected to begin 1H 2025
- TNG260 clinical data expected in 2025
Additional Business and Pipeline Highlights
Leadership Update
Maeve Waldron-Lynch, M.D. will join Tango as Senior Vice President, Head of Clinical Development later this month. In this role, Dr. Waldron-Lynch will lead clinical development functions under Adam Crystal, M.D., Ph.D., President of Research and Development at Tango. Dr. Waldron-Lynch most recently served as VP and Global Clinical Program Head at MorphoSys, where she oversaw the clinical program for tafasitamab. Prior to MorphoSys, she was a Clinical Development Medical Director at Novartis. Dr. Waldron-Lynch also has served as Senior Clinical Director, Oncology at Roche, and as Associate Director of Medical Science, Oncology at Mundipharma. Dr. Waldron-Lynch graduated from the University College Cork School of Medicine and served as a Specialty Registrar Medical Oncology at the Royal College of Physicians of
Financial Results
As of September 30, 2024, the Company held
Collaboration revenue was
License revenue was
Research and development expenses were
General and administrative expenses were
Net loss for the three months ended September 30, 2024 was
About Tango Therapeutics
Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more information, please visit www.tangotx.com.
Forward-Looking Statements
Certain statements in this press release may be considered forward-looking statements. Forward-looking statements generally relate to future events, Tango’s future operating performance and goals, the anticipated benefits of therapies and combination therapies (that include a Tango pipeline product), as well as the expectations, beliefs and development objectives for Tango’s product pipeline and clinical trials. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expect”, “intend”, “will”, “goal”, “estimate”, “anticipate”, “believe”, “predict”, “designed,” “potential” or “continue”, or the negatives of these terms or variations of them or similar terminology. For example, implicit or explicit statements concerning the following include or constitute forward-looking statements: the Company is advancing TNG462 into clinical trials as a monotherapy and with multiple targeted and standard of care combinations, including two RAS(ON) tri-complex inhibitors from Revolution Medicines, Inc.; the Company believes the combination of TNG462 with RAS(ON) inhibitors could be a powerful approach to changing the treatment landscape for pancreatic cancer; potential combination strategies for PRMT5 inhibitors; the Company’s view that TNG462 has the potential to be a best-in-class MTA-cooperative PRMT5 inhibitor in multiple tumor types, including pancreatic and non-small cell lung cancers; the Company is moving TNG462 into full development; the Company expects cash runway into the third quarter of 2026; the Company expects to share another clinical update on TNG462 in 2025; the Company’s planned and ongoing clinical trials, including the anticipated timing for enrollment and the timing to report results and updates of such trials; the Company’s understanding of the central nervous system exposure required to provide meaningful efficacy in glioblastoma and brain metastases; the Company’s plans to enroll patients in a planned Phase 1/2 clinical trial for TNG456 in the first half of 2025; the Company continues to advance TNG260 for cancers with STK11 loss-of-function mutations, with the phase 1/2 clinical trial ongoing; Tango is committed to discovering and delivering the next generation of precision cancer medicines; Dr. Weber’s statements in this press release; and the expected timing of: (i) development candidate declaration for certain targets; (ii) initiating IND-enabling studies; (iii) filing INDs; (iv) clinical trial initiation, dose escalation and dose expansion (including for combination studies) and (v) disclosing initial, interim, additional and final clinical trial results (including for combination studies); and the expected benefits of the Company's development candidates and other product candidates. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Tango and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: the benefits of product candidates seen in preclinical tests and analyses may not be evident when tested in later preclinical studies or in clinical trials or when used in broader patient populations (if approved for commercial sale); Tango has limited experience conducting clinical trials (and will rely on a third party to operate its clinical trials) and may not be able to commence its clinical trials (including opening clinical trial sites, dosing the first patient, and continued enrollment and dosing of an adequate number of clinical trial participants) when expected, may not be able to continue dosing, initiate dose escalation and/or dose expansion on anticipated timelines, and may not generate or report clinical trial results (including final, initial or additional safety, efficacy data and proof-of-mechanism and proof-of-concept) in the anticipated timeframe (or at all); future clinical trial data releases may differ materially from initial or interim data from our current and future clinical trials; Tango’s pipeline products may not be safe and/or effective in humans; Tango has a limited operating history and has not generated any revenue to date from product sales, and may never become profitable; other companies may be able to identify and develop product candidates more quickly than the Company and commercially introduce the product prior to the Company; the Company’s proprietary discovery platform is novel and may not identify any synthetic lethal targets for future development; the Company may not be able to identify development candidates on the schedule it anticipates due to technical, financial or other reasons; the Company may not be able to file INDs for development candidates on time, or at all, due to technical or financial reasons or otherwise; the Company may utilize cash resources more quickly than anticipated; Tango will need to raise capital in the future and if we are unable to raise capital when needed or on attractive terms, we would be forced to delay, scale back or discontinue some of our development programs or future commercialization efforts (which may delay filing of INDs, dosing patients, initiation of dose expansion, reporting clinical trial results and filing new drug applications); Tango’s approach to the discovery and development of product candidates is novel and unproven, which makes it difficult to predict the time, cost of development, and likelihood of successfully developing any products; the Company may be unable to advance our preclinical development programs into and through the clinic for safety or efficacy reasons or commercialize our product candidates or we may experience significant delays in doing so as a result of factors beyond Tango’s control; the Company may not be able to realize the benefits of orphan drug or Fast Track designation (and such designations may not advance any anticipated approval timelines); the expected benefits of our product candidates in patients as single agents and/or in combination may not be realized; the Company may experience delays or difficulties in the initiation, enrollment, or dosing of patients in clinical trials or the announcement of clinical trial results, Tango may not identify or discover additional product candidates or may expend limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success; the Company’s product candidates may cause adverse or other undesirable side effects (or may not show requisite efficacy) that could, among other things, delay or prevent regulatory approval; our dependence on one or a limited number third parties for conducting clinical trials and producing drug substance and drug product (including drug substance, which is currently sole sourced); government regulation may negatively impact the Company’s business, including the potential approval of the BIOSECURE Act; and our ability to obtain and maintain patent and other intellectual property protection for our technology and product candidates or the scope of intellectual property protection obtained is not sufficiently broad. Additional information concerning risks, uncertainties and assumptions can be found in Tango’s filings with the Securities and Exchange Commission (SEC), including the risk factors referenced in Tango’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as supplemented and/or modified by its most recent Quarterly Report on Form 10-Q. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Tango specifically disclaims any duty to update these forward-looking statements.
Consolidated Statements of Operations |
||||||||||||||||
(In thousands, except share and per share data) |
||||||||||||||||
|
Three Months Ended
|
|
|
Nine Months Ended
|
|
|||||||||||
|
|
2024 |
|
|
2023 |
|
|
2024 |
|
|
2023 |
|
||||
Collaboration revenue |
|
$ |
11,607 |
|
|
$ |
10,732 |
|
|
$ |
25,852 |
|
|
$ |
26,096 |
|
License revenue |
|
|
— |
|
|
|
— |
|
|
|
12,100 |
|
|
|
5,000 |
|
Total revenue |
|
|
11,607 |
|
|
|
10,732 |
|
|
|
37,952 |
|
|
|
31,096 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Research and development |
|
|
33,263 |
|
|
|
27,149 |
|
|
|
109,981 |
|
|
|
83,859 |
|
General and administrative |
|
|
11,222 |
|
|
|
9,209 |
|
|
|
32,656 |
|
|
|
26,397 |
|
Total operating expenses |
|
|
44,485 |
|
|
|
36,358 |
|
|
|
142,637 |
|
|
|
110,256 |
|
Loss from operations |
|
|
(32,878 |
) |
|
|
(25,626 |
) |
|
|
(104,685 |
) |
|
|
(79,160 |
) |
Other income, net |
|
|
3,765 |
|
|
|
3,386 |
|
|
|
12,212 |
|
|
|
8,266 |
|
Loss before income taxes |
|
|
(29,113 |
) |
|
|
(22,240 |
) |
|
|
(92,473 |
) |
|
|
(70,894 |
) |
Provision for income taxes |
|
|
(54 |
) |
|
|
(23 |
) |
|
|
(159 |
) |
|
|
(87 |
) |
Net loss |
|
$ |
(29,167 |
) |
|
$ |
(22,263 |
) |
|
$ |
(92,632 |
) |
|
$ |
(70,981 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Net loss per common share – basic and diluted |
|
$ |
(0.27 |
) |
|
$ |
(0.23 |
) |
|
$ |
(0.85 |
) |
|
$ |
(0.78 |
) |
Weighted average number of common shares outstanding – basic and diluted |
|
|
108,507,390 |
|
|
|
97,033,273 |
|
|
|
108,990,011 |
|
|
|
91,268,133 |
|
Consolidated Balance Sheets |
||||||||
(In thousands) |
||||||||
|
September 30,
|
|
|
December 31,
|
|
|||
Assets |
|
|
|
|
|
|
||
Current assets: |
|
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
53,148 |
|
|
$ |
66,385 |
|
Marketable securities |
|
|
240,130 |
|
|
|
270,500 |
|
Restricted cash |
|
|
— |
|
|
|
856 |
|
Prepaid expenses and other current assets |
|
|
7,537 |
|
|
|
8,797 |
|
Total current assets |
|
|
300,815 |
|
|
|
346,538 |
|
Property and equipment, net |
|
|
8,590 |
|
|
|
9,908 |
|
Operating lease right-of-use assets |
|
|
40,430 |
|
|
|
43,508 |
|
Restricted cash, net of current portion |
|
|
2,567 |
|
|
|
2,567 |
|
Other assets |
|
|
13 |
|
|
|
46 |
|
Total assets |
|
$ |
352,415 |
|
|
$ |
402,567 |
|
Liabilities and Stockholders' Equity |
|
|
|
|
|
|
||
Current liabilities: |
|
|
|
|
|
|
||
Accounts payable |
|
$ |
4,112 |
|
|
$ |
2,785 |
|
Accrued expenses and other current liabilities |
|
|
15,006 |
|
|
|
15,401 |
|
Operating lease liabilities |
|
|
2,863 |
|
|
|
2,082 |
|
Deferred revenue |
|
|
15,602 |
|
|
|
25,670 |
|
Total current liabilities |
|
|
37,583 |
|
|
|
45,938 |
|
Operating lease liabilities, net of current portion |
|
|
34,763 |
|
|
|
36,838 |
|
Deferred revenue, net of current portion |
|
|
50,899 |
|
|
|
66,683 |
|
Total liabilities |
|
|
123,245 |
|
|
|
149,459 |
|
Total stockholders’ equity |
|
|
229,170 |
|
|
|
253,108 |
|
Total liabilities and stockholders’ equity |
|
$ |
352,415 |
|
|
$ |
402,567 |
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20241106308250/en/
Investor:
Sam Martin/Andrew Vulis
Argot Partners
tango@argotpartners.com
Media:
Amanda Brown Galgay
SVP, Corporate Communications, Tango Therapeutics
media@tangotx.com
Source: Tango Therapeutics, Inc.
FAQ
What was Tango Therapeutics (TNGX) Q3 2024 revenue?
What is the cash runway for Tango Therapeutics (TNGX)?
What was the clinical efficacy of TNG462 in cholangiocarcinoma?
What was Tango Therapeutics (TNGX) net loss in Q3 2024?
